GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (FRA:PHGN) » Definitions » Cyclically Adjusted FCF per Share

Pharming Group (FRA:PHGN) Cyclically Adjusted FCF per Share : €0.03 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Pharming Group Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Pharming Group's adjusted free cash flow per share for the three months ended in Dec. 2024 was €0.008. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.03 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Pharming Group was 47.70% per year. The lowest was 47.70% per year. And the median was 47.70% per year.

As of today (2025-05-09), Pharming Group's current stock price is €0.795. Pharming Group's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was €0.03. Pharming Group's Cyclically Adjusted Price-to-FCF of today is 26.50.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pharming Group was 66.15. The lowest was 21.82. And the median was 39.13.


Pharming Group Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Pharming Group's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Cyclically Adjusted FCF per Share Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 - 0.02 0.03 0.03

Pharming Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03

Competitive Comparison of Pharming Group's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Pharming Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cyclically Adjusted Price-to-FCF falls into.


;
;

Pharming Group Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharming Group's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.008/131.6300*131.6300
=0.008

Current CPI (Dec. 2024) = 131.6300.

Pharming Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -0.010 99.750 -0.013
201506 -0.013 100.230 -0.017
201509 -0.009 100.500 -0.012
201512 -0.008 99.730 -0.011
201603 -0.008 100.310 -0.010
201606 -0.014 100.260 -0.018
201609 -0.009 100.570 -0.012
201612 0.005 100.710 0.007
201703 -0.012 101.440 -0.016
201706 -0.002 101.370 -0.003
201709 0.022 102.030 0.028
201712 0.047 101.970 0.061
201803 -0.003 102.470 -0.004
201806 0.015 103.100 0.019
201809 0.021 103.950 0.027
201812 0.023 103.970 0.029
201903 0.014 105.370 0.017
201906 0.021 105.840 0.026
201909 0.005 106.700 0.006
201912 0.025 106.800 0.031
202003 0.017 106.850 0.021
202006 0.027 107.510 0.033
202009 0.020 107.880 0.024
202012 0.020 107.850 0.024
202103 0.005 108.870 0.006
202106 0.004 109.670 0.005
202109 0.003 110.790 0.004
202112 0.013 114.010 0.015
202203 0.000 119.460 0.000
202206 0.004 119.050 0.004
202209 0.018 126.890 0.019
202212 0.007 124.940 0.007
202303 -0.033 124.720 -0.035
202306 -0.012 125.830 -0.013
202309 0.005 127.160 0.005
202312 0.012 126.450 0.012
202403 -0.011 128.580 -0.011
202406 -0.014 129.910 -0.014
202409 0.016 131.610 0.016
202412 0.008 131.630 0.008

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Pharming Group  (FRA:PHGN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pharming Group's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=0.795/0.03
=26.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pharming Group was 66.15. The lowest was 21.82. And the median was 39.13.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Pharming Group Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Pharming Group's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Industry
Traded in Other Exchanges
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines